Swissmedic
REGULATORY UPDATE
Change to the review practice for medicinal products containing the active substance paclitaxel as paclitaxel albumin
Published: 12/15/2025Detected: 3/26/2026
Summary preview
Introduces a change in Swiss regulatory review practice for medicinal products whose active substance is paclitaxel presented as paclitaxel albumin, potentially altering expectations for how such applications are…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountOfficial Source Document Source Verified
Access the original document directly from SWISSMEDIC.
More from Swissmedic
- Extended deadline for publishing officially mandated information materials on the electronic publication platform11/12/2026
- Designer drugs: FDHA brings further psychoactive substances under control11/10/2026
- NAD+ supplements: When lifestyle products have criminal consequences11/9/2026
- Publication eCTD v4.0 Implementation Guide Package v2.011/9/2026
- Save the Date: Clinical Trials Symposium 202711/4/2026